169 related articles for article (PubMed ID: 37402468)
1. Development of orphan drugs for rare diseases.
Yoo HW
Clin Exp Pediatr; 2024 Jul; 67(7):315-327. PubMed ID: 37402468
[TBL] [Abstract][Full Text] [Related]
2. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.
Tambuyzer E; Vandendriessche B; Austin CP; Brooks PJ; Larsson K; Miller Needleman KI; Valentine J; Davies K; Groft SC; Preti R; Oprea TI; Prunotto M
Nat Rev Drug Discov; 2020 Feb; 19(2):93-111. PubMed ID: 31836861
[TBL] [Abstract][Full Text] [Related]
3. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
4. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop.
Mikami K; Sturdy S
Res Involv Engagem; 2017; 3():14. PubMed ID: 29062539
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Orphan drug development: Challenges, regulation, and success stories.
Chirmule N; Feng H; Cyril E; Ghalsasi VV; Choudhury MC
J Biosci; 2024; 49():. PubMed ID: 38383975
[TBL] [Abstract][Full Text] [Related]
7. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
8. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
9. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
Menon D; Stafinski T; Dunn A; Short H
Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
[TBL] [Abstract][Full Text] [Related]
10. Innovative Genoceuticals in Human Gene Therapy Solutions: Challenges and Safe Clinical Trials of Orphan Gene Therapy Products.
Sharma R
Curr Gene Ther; 2024; 24(1):46-72. PubMed ID: 37702177
[TBL] [Abstract][Full Text] [Related]
11. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases.
Aoki Y; Wood MJA
J Neuromuscul Dis; 2021; 8(6):869-884. PubMed ID: 34092651
[TBL] [Abstract][Full Text] [Related]
12. Insurance companies' perspectives on the orphan drug pipeline.
Handfield R; Feldstein J
Am Health Drug Benefits; 2013 Nov; 6(9):589-98. PubMed ID: 24991385
[TBL] [Abstract][Full Text] [Related]
13. Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Mulberg AE; Bucci-Rechtweg C; Giuliano J; Jacoby D; Johnson FK; Liu Q; Marsden D; McGoohan S; Nelson R; Patel N; Romero K; Sinha V; Sitaraman S; Spaltro J; Kessler V
Orphanet J Rare Dis; 2019 Feb; 14(1):36. PubMed ID: 30736861
[TBL] [Abstract][Full Text] [Related]
14. A generalizable pre-clinical research approach for orphan disease therapy.
Beaulieu CL; Samuels ME; Ekins S; McMaster CR; Edwards AM; Krainer AR; Hicks GG; Frey BJ; Boycott KM; Mackenzie AE
Orphanet J Rare Dis; 2012 Jun; 7():39. PubMed ID: 22704758
[TBL] [Abstract][Full Text] [Related]
15. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
16. Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.
Pandina GJ; Busner J; Kempf L; Fallon J; Alphs LD; Acosta MT; Berger AK; Day S; Dunn J; Villalta-Gil V; Grabb MC; Horrigan JP; Jacobson W; Kando JC; Macek TA; Singh MK; Stanford AD; Domingo SZ
Innov Clin Neurosci; 2024; 21(1-3):52-60. PubMed ID: 38495603
[TBL] [Abstract][Full Text] [Related]
17. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
18. Regulatory environment for novel therapeutic development in mitochondrial diseases.
Hirano M; Berardo A; Barca E; Emmanuele V; Quinzii C; Simpson CV; Engelstad K; Rosales XQ; Thompson JLP
J Inherit Metab Dis; 2021 Mar; 44(2):292-300. PubMed ID: 33368420
[TBL] [Abstract][Full Text] [Related]
19. Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals.
Miller KL; Lanthier M
Health Aff (Millwood); 2024 Jan; 43(1):18-26. PubMed ID: 38190603
[TBL] [Abstract][Full Text] [Related]
20. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
Sheikh O; Yokota T
Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
